B F Barna1, A C Takakura2, D K Mulkey3, T S Moreira1. 1. Department of Physiology and Biophysics, Institute of Biomedical Science, University of São Paulo, São Paulo, SP, Brazil. 2. Department of Pharmacology, Institute of Biomedical Science, University of São Paulo, São Paulo, SP, Brazil. 3. Department of Physiology and Neurobiology, University of Connecticut, Storrs, CT, USA.
Abstract
AIM: Recent evidence suggests that adenosine triphosfate (ATP)-mediated purinergic signalling at the level of the rostral ventrolateral medulla contributes to both central and peripheral chemoreceptor control of breathing and blood pressure: neurones in the retrotrapezoid nucleus (RTN) function as central chemoreceptors in part by responding to CO2 -evoked ATP release by activation of yet unknown P2 receptors, and nearby catecholaminergic C1 neurones regulate blood pressure responses to peripheral chemoreceptor activation by a P2Y1 receptor-dependent mechanism. However, potential contributions of purinergic signalling in the RTN to cardiorespiratory function in conscious animals have not been tested. METHODS: Cardiorespiratory activity of unrestrained awake rats was measured in response to RTN injections of ATP, and during exposure to hypercapnia (7% CO2 ) or hypoxia (8% O2 ) under control conditions and after bilateral RTN injections of P2 receptor blockers (PPADS or MRS2179). RESULTS: Unilateral injection of ATP into the RTN increased cardiorespiratory output by a P2-receptor-dependent mechanism. We also show that bilateral RTN injections of a non-specific P2 receptor blocker (pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS) reduced the ventilatory response to hypercapnia (7% CO2 ) and hypoxia (8% O2 ) in unanesthetized rats. Conversely, bilateral injections of a specific P2Y1 receptor blocker (MRS2179) into the RTN had no measurable effect on ventilatory responses elicited by hypercapnia or hypoxia. CONCLUSION: These data exclude P2Y1 receptor involvement in the chemosensory control of breathing at the level of the RTN and show that ATP-mediated purinergic signalling contributes to central and peripheral chemoreflex control of breathing and blood pressure in awake rats.
AIM: Recent evidence suggests that adenosine triphosfate (ATP)-mediated purinergic signalling at the level of the rostral ventrolateral medulla contributes to both central and peripheral chemoreceptor control of breathing and blood pressure: neurones in the retrotrapezoid nucleus (RTN) function as central chemoreceptors in part by responding to CO2 -evoked ATP release by activation of yet unknown P2 receptors, and nearby catecholaminergic C1 neurones regulate blood pressure responses to peripheral chemoreceptor activation by a P2Y1 receptor-dependent mechanism. However, potential contributions of purinergic signalling in the RTN to cardiorespiratory function in conscious animals have not been tested. METHODS: Cardiorespiratory activity of unrestrained awake rats was measured in response to RTN injections of ATP, and during exposure to hypercapnia (7% CO2 ) or hypoxia (8% O2 ) under control conditions and after bilateral RTN injections of P2 receptor blockers (PPADS or MRS2179). RESULTS: Unilateral injection of ATP into the RTN increased cardiorespiratory output by a P2-receptor-dependent mechanism. We also show that bilateral RTN injections of a non-specific P2 receptor blocker (pyridoxal-phosphate-6-azophenyl-2',4'-disulfonate (PPADS) reduced the ventilatory response to hypercapnia (7% CO2 ) and hypoxia (8% O2 ) in unanesthetized rats. Conversely, bilateral injections of a specific P2Y1 receptor blocker (MRS2179) into the RTN had no measurable effect on ventilatory responses elicited by hypercapnia or hypoxia. CONCLUSION: These data exclude P2Y1 receptor involvement in the chemosensory control of breathing at the level of the RTN and show that ATP-mediated purinergic signalling contributes to central and peripheral chemoreflex control of breathing and blood pressure in awake rats.
Authors: Robert T R Huckstepp; Rachid id Bihi; Robert Eason; K Michael Spyer; Nikolai Dicke; Klaus Willecke; Nephtali Marina; Alexander V Gourine; Nicholas Dale Journal: J Physiol Date: 2010-08-24 Impact factor: 5.182
Authors: Louise Meigh; Sophie A Greenhalgh; Thomas L Rodgers; Martin J Cann; David I Roper; Nicholas Dale Journal: Elife Date: 2013-11-12 Impact factor: 8.140
Authors: Bárbara Falquetto; Luiz M Oliveira; Ana C Takakura; Daniel K Mulkey; Thiago S Moreira Journal: Neuropharmacology Date: 2018-05-23 Impact factor: 5.250
Authors: Janayna D Lima; Cleyton R Sobrinho; Barbara Falquetto; Leonardo K Santos; Ana C Takakura; Daniel K Mulkey; Thiago S Moreira Journal: J Physiol Date: 2019-03-01 Impact factor: 5.182
Authors: Camilo Toledo; Esteban Díaz-Jara; Hugo S Diaz; Karla G Schwarz; Katherin V Pereyra; Alexandra Las Heras; Angélica Rios-Gallardo; David C Andrade; Thiago Moreira; Ana Takakura; Noah J Marcus; Rodrigo Del Rio Journal: EBioMedicine Date: 2022-05-09 Impact factor: 11.205
Authors: Yingtang Shi; Ruth L Stornetta; Daniel S Stornetta; Suna Onengut-Gumuscu; Emily A Farber; Stephen D Turner; Patrice G Guyenet; Douglas A Bayliss Journal: J Neurosci Date: 2017-10-24 Impact factor: 6.167
Authors: Cleyton R Sobrinho; Christopher M Gonçalves; Ana C Takakura; Daniel K Mulkey; Thiago S Moreira Journal: J Neurophysiol Date: 2017-07-05 Impact factor: 2.714
Authors: Thiago S Moreira; Cleyton R Sobrinho; Barbara Falquetto; Luiz M Oliveira; Janayna D Lima; Daniel K Mulkey; Ana C Takakura Journal: J Neurophysiol Date: 2020-12-02 Impact factor: 2.714
Authors: Camilo Toledo; Domiziana Ortolani; Fernando C Ortiz; Noah J Marcus; Rodrigo Del Rio Journal: Front Physiol Date: 2022-04-12 Impact factor: 4.755